Physician profile
Phillip Ahn
NPI 1376527879
$7,835.61
in general payments reported to CMS, 2019-2025
13 companies · $3,240 in 2025
The $3,240 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,939 · 2020: $627 · 2021: $976 · 2022: $302 · 2023: $244 · 2024: $508 · 2025: $3,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,078 · Food and Beverage: $767 · Travel and Lodging: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,078.00 |
| Food and Beverage | $767.22 |
| Travel and Lodging | $147.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,465.05 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $1,559.66 | 2019-2022 | |
| Novo Nordisk INC | $982.83 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $566.36 | 2019-2021 | |
| Chugai Pharmaceutical Co., Ltd. | $422.00 | 2021 | |
| Amgen INC. | $270.52 | 2019 | |
| Glaxosmithkline, LLC. | $225.72 | 2019-2025 | Rotarix, Penmenvy, Bexsero |
| Pfizer INC. | $142.69 | 2019-2020 | |
| Boston Scientific Corporation | $87.21 | 2019 | |
| Horizon Therapeutics Plc | $40.76 | 2020-2021 | |
| Axsome Therapeutics, INC. | $29.55 | 2025 | Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.83 | 2020 | |
| Gilead Sciences, INC. | $20.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.